v3.25.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities      
Net loss $ (94,981) $ (96,915) $ (82,842)
Adjustments to reconcile net loss to net cash used in operations:      
Depreciation and amortization 5,824 6,920 7,864
Bargain purchase gain, net of tax (1,669)
Loss (gain) on disposal of fixed assets 143 (34)
Unrealized (gain) loss on derivative liability (5,709) 8,866
Unrealized gain on warrant liability (4,422)
Loss on debt extinguishment 4,654
Impairment of intangible assets 10,057 4,181
Impairment of operating lease right-of-use assets 1,201 405
Impairment of property and equipment 2,185 12
Inventory write-downs 9,864 2,045 76
Non-cash interest expense 7,325
Amortization of debt discount and issuance costs on notes payable 11,164 4,382
Share-based compensation expense 701 11,535 16,141
Net accretion of premium on short-term investments (532) (951) (1,275)
Change in:      
Accounts receivable 879 23 (949)
Inventory (8,276) (495) (892)
Other current and non-current assets 1,858 85 (2,096)
Accounts payable 496 (1,139) 942
Accrued liabilities 2,884 (6,098) 6,571
Contract liabilities and other current liabilities (399) (188) (6,452)
Operating lease liabilities (3,036) (2,491) (2,500)
Other long-term liabilities (457) 1,152 13
Net cash used in operating activities (58,720) (68,540) (67,090)
Cash flows from investing activities      
Sales of investment securities 30,134 35,411 76,700
Purchases of investment securities (51,859) (26,065) (41,710)
Advance to Scantinel (2,244)
Cash paid for Ibeo business combination (6,300) (11,233)
Purchases of property and equipment (679) (374) (1,935)
Net cash provided by (used in) investing activities (24,648) 2,672 21,822
Cash flows from financing activities      
Principal payments under finance leases (13) (21)
Principal payments under notes payable (16,500)
Principal proceeds from notes payable, net of debt discount and issuance costs 38,080
Proceeds from stock option exercises 8 62 175
Net proceeds from issuance of common stock and warrants 77,374 34,748 72,284
Net cash provided by financing activities 60,869 72,890 72,438
Effect of exchange rate changes on cash and cash equivalents and restricted cash 316 (166) 267
Change in cash, cash equivalents, and restricted cash (22,183) 6,856 27,437
Cash, cash equivalents, and restricted cash at beginning of period 56,247 49,391 21,954
Cash, cash equivalents, and restricted cash at end of period 34,064 56,247 49,391
Supplemental schedule of non-cash investing and financing activities      
Common stock issued in conversion of note payable 21,980 3,745
Issuance of warrants 6,297
Amounts issued to escrow for acquisition consideration 6,300
Acquisition of right-of-use asset 137 5,395 1,338
Accrued financing fees (32)
Foreign currency translation adjustments 671 (210) 184
Unrealized (loss) gain on investment securities, available-for-sale $ (2) $ 153

Source

HTML PDF
ZIP